Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Acadia Pharmaceuticals (ACAD) announced that it has signed an exclusive worldwide license agreement with Saniona, a Denmark-based clinical-stage biopharmaceutical company, to develop and commercialize SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. As its first indication, Acadia plans to study SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. The company is gearing up to initiate a mid-stag ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sco ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE . Today, we are circling back to ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) . I called this mid-cap biopharma back in the "buy zone" when I posted an article on this name in June, ...

Acadia Pharmaceuticals (ACAD) reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate of 13 cents. In the year-ago quarter, the company had incurred a loss of 40 cents per share. Acadia recorded total revenues of $250 million, which beat the Zacks Consensus Estimate of $249 million. ACAD's net product revenues comprise revenues generated from the sale of its two marketed products, Nuplazid (pimavanserin) and the newly launched Daybue (trofinetide). ACAD's first drug, ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Al Kildani - SVP, IR and Corporate Communications Catherine Owen-Adams - CEO Brendan Teehan - COO, Head of Commercial Liz Thompson - EVP, Head of Research and Development Mark Schneyer - CFO Conference Call Participants Gregory Renza - RBC Capital Markets Jason Butler - Citizens JMP Joe Beatty - Baird Keith Tapper - BMO Capital Markets Tazeen Ahmad - Bank of America Jeff Hung - Morgan ...

() ACADIA Third Quarter 2024 Earnings Call November 6, 2024 Call Agenda CEO Opening Remarks Catherine Owen Adams | Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Elizabeth H.Z. Thompson | Executive Vice President, Head of Research and Development Financial Update Mark Schneyer | Chief Financial Officer Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications Closing Remarks Catherine Owen Adams | Chief Exec ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 53.85%. A quarter ago, it was expected that this drugmaker would post earnings of $0.16 per share when it actually produced earnings of $0.20, delivering a surprise of 25%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No ...

Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year SAN DIEGO, CA, November 6, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The ...